Amanda Jimenez

Dr. Amanda Jimenez


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2020 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
JMJudit Molero
Judit Molero
VMVioleta Moizé
Violeta Moizé
LFLiliam Flores
Liliam Flores
Ana de HollandaAna de Hollanda
Ana de Hollanda
AJAmanda Jimenez
Amanda Jimenez
JVJosep Vidal
Josep Vidal


24 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
ÓOÓscar Osorio-Conles
Óscar Osorio-Conles
RORomina Olbeyra
Romina Olbeyra
VMVioleta Moizé
Violeta Moizé
AIAinitze Ibarzabal
Ainitze Ibarzabal
OGOriol Giró
Oriol Giró
Ana de HollandaAna de Hollanda
Ana de Hollanda
It has been suggested that weight-loss-independent Mediterranean diet benefits on cardiometabolic health and diabetes prevention may be mediated, at least in part, through the modulation of white adipose tissue (WAT) biology. This study aimed to evaluate the short-term effects of a dietary intervention based on the Mediterranean diet supplemented with almonds (MDSA) on the main features of obesity-associated WAT dysfunction. A total of 38 women with obesity were randomly assigned to a 3-month intervention with MDSA versus continuation of their usual dietary pattern. Subcutaneous (SAT) and visceral adipose tissue (VAT) biopsies were obtained before and after the dietary intervention, and at the end of the study period, respectively. MDSA favored the abundance of small adipocytes in WAT. In SAT, the expression of angiogenesis genes increased after MDSA intervention. In VAT, the expression of genes implicated in adipogenesis, angiogenesis, autophagy and fatty acid usage was upregulated. In addition, a higher immunofluorescence staining for PPARG, CD31+ cells and M2-like macrophages and increased ADRB1 and UCP2 protein contents were found compared to controls. Changes in WAT correlated with a significant reduction in circulating inflammatory markers and LDL-cholesterol levels. These results support a protective effect of a Mediterranean diet supplemented with almonds on obesity-related WAT dysfunction.

6 June 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
GCGemma Chiva-Blanch
Gemma Chiva-Blanch
CJClaudia Jiménez
Claudia Jiménez
MPMontserrat Pinyol
Montserrat Pinyol
ZHZoe Herreras
Zoe Herreras
MCMarta Catalán
Marta Catalán
EOEmilio Ortega
Emilio Ortega
Diabetic subjects are at increased risk of cardiovascular disease. Atherosclerosis, the common soil of most of the cardiovascular complications, is more prevalent and extensive in this population due not only to hyperglycemia, insulin resistance, and dyslipidemia, but also to inflammation and oxidative stress. Lycopenes are bioactive compounds with antioxidant and anti-inflammatory activities mostly supplied by tomato and tomato byproducts. We investigated the association between circulating lycopenes and carotid plaque burden in diabetic patients, in a cross-sectional study in 105 newly diagnosed diabetic subjects. Atheroma plaque (wall thickness ≥ 1.5 mm), number of plaques, and plaque burden (sum of maximum heights of all plaques) were assessed by sonographic evaluation of carotid arteries. Plasma lycopenes (5-cis-, 9-cis-, 13-cis-, and trans-lycopene) were quantified by high performance liquid chromatography–mass spectrometry HPLC-MS. Atheroma plaque was observed in 75 participants, from which 38 presented one plaque and 37 two or more carotid plaques. No differences were observed in the plasmatic concentrations of lycopenes between subjects with and without atherosclerotic plaque presence. However, plaque burden was inversely associated with 5-cis-lycopene, all cis-lycopene isomers, trans-lycopene, and total lycopene isomers (all, p < 0.05). High plasma levels of lycopenes inversely relate to atherosclerotic burden. We provide novel evidence that suggests that the consumption of compounds found in tomato and tomato byproducts might be beneficial for the prevention of atherosclerosis.

1 January 2020 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Verified
Journal Article
Open access
PDF file
JPJordi Pegueroles
Jordi Pegueroles
APAdriana Pané
Adriana Pané
EVEduard Vilaplana
Eduard Vilaplana
VMVíctor Montal
Víctor Montal
ABAlexandre Bejanin
Alexandre Bejanin
AIAlzheimer'S Disease Neuroimaging Initiative
Alzheimer'S Disease Neuroimaging Initiative
Aims/hypothesis Midlife obesity is a risk factor for dementia. We investigated the impact of obesity on brain structure, metabolism, and cerebrospinal fluid (CSF) core Alzheimer's disease (AD) biomarkers in healthy elderly. Methods We selected controls from ADNI2 with CSF AD biomarkers and/or fluorodeoxyglucose positron emission tomography (FDG‐PET) and 3T‐MRI. We measured cortical thickness, FDG uptake, and CSF amyloid beta (Aβ)1‐42, p‐tau, and t‐tau levels. We performed regression analyses between these biomarkers and body mass index (BMI). Results We included 201 individuals (mean age 73.5 years, mean BMI 27.4 kg/m2). Higher BMI was related to less cortical thickness and higher metabolism in brain areas typically not involved in AD (family‐wise error [FWE] <0.05), but not to AD CSF biomarkers. It is notable that the impact of obesity on brain metabolism and structure was also found in amyloid negative individuals. Conclusions/interpretation In the cognitively unimpaired elderly, obesity has differential effects on brain metabolism and structure independent of an underlying AD pathophysiology.

21 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
APAdriana Pané
Adriana Pané
MCMaria Claro
Maria Claro
AAAlícia Molina Andújar
Alícia Molina Andújar
RORomina Olbeyra
Romina Olbeyra
BRBarbara Romano-Andrioni
Barbara Romano-Andrioni
Ana de HollandaAna de Hollanda
Ana de Hollanda
Obesity increases the risk of developing chronic kidney disease (CKD), which has a major negative impact on global health. Bariatric surgery (BS) has demonstrated a substantial improvement of obesity-related comorbidities and thus, it has emerged as a potential therapeutic tool in order to prevent end-stage renal disease. A limited number of publications to date have examined the beneficial effects and risks of BS in patients with non-advanced stages of CKD. We aimed to investigate the safety of BS in patients with CKD stages 3–4 (directly related or not to obesity) and both the metabolic/renal outcomes post-BS. A total of 57 individuals were included (n = 19 for CKD-group; n = 38 for patients with obesity, but normal eGFR [control-group]). Weight loss and obesity comorbidities resolution after BS were similar in both groups. Renal function (eGFR [CKD-EPI]) improved significantly at the 1-year follow-up: Δ10.2 (5.2–14.9) (p < 0.001) for CKD-group and Δ4.0 (−3.9–9.0) mL/min/1.73 m2 (p = 0.043) for controls. Although this improvement tended to decrease in the 5-year follow-up, eGFR remained above its basal value for the CKD-group. Noteworthy, eGFR also improved in those patients who presented CKD not directly attributed to obesity. For patients with CKD, BS appears to be safe and effective regarding weight loss and obesity comorbidities resolution, irrespective of the main cause of CKD (related or not to obesity).